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Background: We examined the feasibility and efficacy of using a non-mydriatic camera to screen for diabetic
retinopathy (DR) among youth with type 1 or type 2 diabetes seen in a pediatric endocrinology clinic serving
Alabama, the state that has the highest diabetes rate in the United States.
Methods: 236 youths with type 1 or type 2 diabetes were screened for DR using a non-mydriatic camera. Visual
acuity was also assessed. A questionnaire asked parents about diabetes and eye care history.
Results: Mean duration since diabetes diagnosis was 5.5 years. 66 % reported receiving an eye examination within
the previous year. 97.5 % had images that were gradable. DR was detected in 3.8 % of participants. 9.1 % were
visually impaired.
Conclusions: Use of a non-mydriatic fundus camera is feasible and efficacious for DR screening in youth with
diabetes. DR screening at routine endocrinology visits may be beneficial in managing youth with diabetes and
preventing irreversible vision loss, particularly for those in regions where diabetes rates are high.
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Diabetes is a significant, worldwide burden that has dra-
matically increased in recent years with no evidence of
the trend abating. Of particular concern is the rise in
both type 1 and type 2 diabetes among youth which has
increased by 21.1 % and 30.5 %, respectively, from 2001
to 2009 [1]. As these rates increase, the number of youth
with diabetic-related complications will also increase.
Among these complications is diabetic retinopathy (DR)
and associated vision loss. DR is the leading cause of
new cases of blindness among young adults in the
United States [2].
It is established that the risk of DR increases with dur-
ation of diabetes [3–5]. Retinopathy may not produce* Correspondence: owsley@uab.edu
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early detection and treatment is important in reducing
rates of diabetes related vision problems [6, 7]. However,
findings from the SEARCH for Diabetes in Youth study
showed that only two-thirds of those under age 18 years
with type 1 and type 2 diabetes receive an annual com-
prehensive dilated eye exam, making it the least com-
monly followed of the American Diabetes Association
(ADA) guidelines for diabetes care in youth [8]. Youth
with diabetes were also less likely to obtain annual eye
exams than their adult counterparts [9]. Multiple factors
may contribute to this low rate of dilated eye examin-
ation, such as cost, inconvenience of visiting an eye care
provider, transportation challenges, or insufficient know-
ledge about the risk of DR.
For adults with diabetes, non-mydriatic fundus cam-
eras have been implemented as screening tools for
DR [10–12]. These cameras are non-invasive, painless,ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Diabetic retinopathy (DR) grading based on the
National Health Service Grading Classification System [17]
with follow-up recommendations adapted from the American
Academy of Ophthalmology [18]
Grade Description Recommendation
R0 No diabetic retinopathy Re-evaluate in twelve months with
either eye care provider or
photographic screening
R1 Background DR Refer to eye care provider
R2 Pre-proliferative DR Refer to ophthalmologist promptly
R3 Proliferative DR Refer to ophthalmologist promptly
M Maculopathy Refer to ophthalmologist promptly
P Photocoagulation Refer to eye care provider
U Unclassifiable/Ungradable Refer to eye care provider
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images that reveal most clinically significant cases of DR.
Those who screen positive can be recommended for a
follow-up dilated comprehensive eye examination by an
ophthalmologist or optometrist. However, this screening
approach has not been widely implemented in youth
with diabetes, and few studies have evaluated its feasi-
bility and potential usefulness in pediatric screening for
DR [13–15]. The primary objective of this study was to
examine the feasibility and efficacy of non-mydriatic dia-
betic retinopathy screening in youth with type 1 or type
2 diabetes seeking regular diabetes care in a pediatric
endocrinology clinic located in Alabama, the state in the
US having the highest rate of diabetes [16].
Methods
This study was conducted at the Pediatric Endocrinology
Clinic of the University of Alabama at Birmingham
(UAB). This clinic largely serves the state of Alabama, as
well as regions of eastern Mississippi and the Florida
panhandle. The study population consisted of youth with
a clinical diagnosis of either type 1 or type 2 diabetes,
ages 8 to 18 years, who attended this clinic. Diabetes diag-
nosis and type were confirmed by endocrinologists at the
clinic. Approval from the Institutional Review Board of
UAB was obtained prior to the study’s initiation.
Those meeting the inclusion criteria were identified
through the endocrinology clinic’s appointment schedule
for the period of June to August 2013. Parents/guardians
of eligible youth were mailed a letter describing the
study two weeks prior to the youth’s appointment invit-
ing participation at his/her next diabetes clinic visit. At
that visit, a research assistant determined if the parent/
guardian and youth were interested in participating. Par-
ticipants were enrolled after obtaining informed consent
from the parent/guardian and assent from the youth. A
brief survey was administered to the parent/guardian
obtaining information on the youth’s history of diabetes,
eye care utilization, barriers to receiving eye care, and
demographic information. Information was obtained
from the medical record on HbA1c, urine microalbumin,
and lipid profile (total cholesterol, low-density lipopro-
tein cholesterol (LDL-C), high-density lipoprotein chol-
esterol (HDL-C), and triglycerides.
Walk-in letter acuity was assessed for each eye using the
TitmusV2 Vision Screener (Sperian Protection Optical,
Inc., Chester, VA). Ocular imaging was performed by a
trained research assistant using a non-mydriatic fundus
camera with autofocus (Model AFC-230, Nidek Inc.,
Fremont, CA) in a dimly lit room. The youth was posi-
tioned in a forehead/chin rest in front of the camera in a
seated position. Three images from each eye were taken:
the anterior segment of the eye and two images of the fun-
dus (macula centered view and optic nerve head view). Ifthe images were blurry or the youth blinked, additional
images were taken to achieve good image quality. Testing
lasted about five minutes.
Within one week of screening, the images were re-
viewed and graded for DR by an ophthalmologist spe-
cializing in retinal/vitreal disease using the UK National
Health System’s classification system for diabetic retin-
opathy (Table 1) [17]. The ophthalmologist also noted
ocular findings other than DR. Screening results were
made available to the endocrinologist, and a letter was
generated and sent to the parent/guardian of each par-
ticipant describing screening results and follow up rec-
ommendations. Recommendations were adapted from
the American Academy of Ophthalmology’s guidelines
for DR follow-up [18]. Participants who screened nega-
tive for DR (R0) were sent a letter that encouraged them
to make appointments for dilated eye examinations on
an annual basis. Participants who screened positive for
background DR (R1) or photocoagulation (P) were sent
a letter that encouraged follow-up with an eye care pro-
vider “in the next few months” for a dilated compre-
hensive eye exam. Participants with pre-proliferative
(R2), proliferative (R3), or maculopathy (M) were sent a
letter describing the need for urgent referral to an oph-
thalmologist. Those who screened positive for any DR
(R1, R2, R3, or M) were additionally telephoned by the
endocrinologist to describe the results and need for re-
ferral. Participants with any of the six images determined
unclassifiable/ungradable due to image quality (U) were
sent a letter encouraging to follow-up with a compre-
hensive dilated eye examination.
Statistical analysis
Participants were categorized into one of three mutually
exclusive eye care utilization groups, i.e., ≤12 months,
>12 months, and never, based on parent/guardian survey
responses regarding their child’s most recent eye care
visit. Information on HbA1c and lipid profile (total
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tegorized based on gender and age specific norms.
Specifically, HbA1c was high if ≥8.5 % (69 mmol/mol)
for <6 years of age; ≥8.0 % (64 mmol/mol) for 6–12
years of age; ≥7.5 % (58 mmol/mol) for 13–19 years of
age [2]. Lipids were stratified into percentile categories
according to published standards [19]. Urine albumin re-
sults were classified as normal (<30 mg/L), microalbumi-
nuria (30–299 mg/L), and macroalbuminuria (>300 mg/L)
[20]. Eye care utilization categories were compared for sig-
nificant differences using analysis of variance for con-
tinuous variables, and Chi-square tests and Fisher’s exact
tests, for categorical variables.
Results
We identified 575 eligible youths through the appoint-
ment schedule and sent letters describing the study. Of
these, 252 (44 %) youths were approached in the clinic
and invited to participate. The remaining youth were not
approached if they were already being seen by the endo-
crinologist/nurse or were “no-shows” for their appoint-
ments; thus, they were unavailable for recruitment. Of the
252 youths approached for participation, 236 (92.9 %)
consented to screening. Mean age for participants was
14.1 ± 2.7 years and 135 (57.2 %) were female (Table 2).
In terms of race, 67.0 % were white, 29.7 % African
American, and the remaining were Hispanic, Native
American, or Asian.
Among the study participants, 85.6 % had type 1 dia-
betes and 14.4 % had type 2 diabetes (Table 2). Mean
age at diabetes diagnosis was 8.6 ± 3.9 years, and mean
duration of diabetes was 5.5 ± 3.5 years. HbA1c level was
“high” in terms of age in 71.6 % of participants. Choles-
terol, LDL, HDL, and triglycerides levels were greater
than the 75th percentile in 34.4 %, 22.5 %, 80.9 %, and
56.4 % of participants, respectively. Urine albumin was
normal (<30 mg/L) in 90.3 % of participants.
66.1 % of participants reported receiving a dilated com-
prehensive eye examination within the past 12 months,
19.9 % had an examination more than 12 months ago, and
14.0 % had never received an examination (Table 2).
Those who had never received an eye examination tended
to be younger than those who did have one, although this
was not statistically significant (p = 0.142). Those who had
an eye examination in the past 12 months were more
likely to be diagnosed with diabetes at a younger age
(p = 0.053) and have a longer duration of diabetes
(p = 0.001). All but one parent/guardian responded that
they were capable of taking their child to an ophthalmolo-
gist or optometrist to receive a comprehensive dilated eye
exam if necessary.
All participants were able to cooperate in sitting before
the camera. Images from 6 participants (2.5 %) were de-
termined unreadable (a single eye for 2 and both eyesfor 4). All unreadable images were due to the youth’s in-
ability to keep their eyes open during the photographic
flash. Mean age for participants with unreadable images
was 14.4 years, which was not different than the mean
age of participants with readable images (p = 0.733).
Nine participants (3.9 %) had DR in at least one eye,
the majority of which was background DR (Table 3).
One participant with background DR showed signs of
maculopathy, and one participant displayed evidence of
previous photocoagulation treatment. Ten participants
(4.3 %) had other types of ocular findings detected in at
least one eye. These included venous loop, media opaci-
ties, choroidal coloboma, white centered hemorrhage,
pale/abnormal disc, increased cup/disc ratio, and atro-
phic macular scar. Having any DR (n = 9) was associated
with duration of diabetes (mean duration 7.8 ± 3.7 years
with retinopathy versus 5.4 ± 3.5 years without retinop-
athy, p = 0.046). There were no associations between DR
presence and other variables, including age at diagnosis,
diabetes type and clinical laboratory values.
A sensitivity analysis restricting the study group to
those who met ADA guidelines for recommended di-
lated comprehensive eye examination was performed
(i.e., for type 1, a dilated comprehensive eye examina-
tion is recommended at the start of puberty or at
age ≥10 years, whichever is earlier, once the child has
had diabetes for 3–5 years, with annual follow-up there-
after; for type 2, a dilated eye examination is recom-
mended at diagnosis, and then annually thereafter) [2].
This analysis included 140/202 (69.3 %) of participants
with type 1 diabetes and all 34 participants with type 2
diabetes. Of the 174 participants who met ADA criteria
for dilated examination, two subjects had unclassifiable/
ungradable images for both eyes. Among the 172 partici-
pants with readable images, eight (4.7 %) subjects had
DR in at least one eye, i.e., six (3.5 %) had background
DR and two (1.2 %) had proliferative DR.
Overall, 115 participants (49.8 %) had corrective lenses
(either glasses or contact lenses); of these, 54 partici-
pants (23.4 %) did not bring their corrective lenses to
the appointment. Acuity was measured in all partici-
pants, even if they did not have their corrective lenses.
Table 4 provides acuity screening results for the better
and worse seeing eyes; 24.2 % of participants had 20/20
acuity in both eyes; 58.4 % of participants had worse
than 20/20 acuity in the better seeing eye, and 75.8 %
had worse than 20/20 in the worse seeing eye. 19.5 % of
participants met the criteria for visual impairment, de-
fined as 20/40 or worse in the better seeing eye.
Because almost one fourth of the sample had cor-
rective lenses but did not bring them, results could be
influenced by a refractive error that is normally cor-
rected. When Table 4 excluded participants who did not
bring their lenses, only 29.4 % had 20/20 acuity in both
Table 2 Demographic, clinical, and laboratory characteristics of participants by recency of dilated eye examination
Total
(N = 236)
Eye exam≤ 12 months
(N = 156)






Age, years, mean (standard deviation, SD) 14.1 (2.69) 14.1 (2.58) 14.9 (2.7) 12.8 (2.8) 0.142
Minimum - maximum 8.0-18.9 8.0-18.9 9.4-18.9 8.3-18.4
Gender, N (%)
Male 101 (42.8) 68 (43.6) 22 (46.8) 11 (33.3) 0.459
Female 135 (57.2) 88 (56.4) 25 (53.2) 22 (66.7)
Race, N (%)
White, non-Hispanic origin 158 (67.0) 109 (69.9) 25 (59.6) 21 (63.6) 0.225
African American 70 (29.7) 43 (27.6) 17 (36.2) 10 (30.3)
Hispanic 5 (2.1) 3 (1.9) 0 (0) 2 (6.1)
Native American 2 (0.9) 1 (0.6) 1 (2.1) 0 (0)
Asian 1 (0.4) 0 (0) 1 (2.1) 0 (0)
Clinical characteristics
Type, n (%) 0.824
Type 1 202 (85.6) 135 (86.6) 39 (83.0) 28 (84.8)
Type 2 34 (14.4) 21 (13.5) 8 (17.0) 5 (16.0)
Age at diabetes diagnosis, years, mean (SD) 8.6 (3.9) 8.2 (4.0) 9.6 (4.0) 9.2 (3.5) 0.053
Duration of diabetes diagnosis, years, mean (SD) 5.5 (3.5) 5.9 (3.4) 5.4 (4.0) 3.6 (2.5) 0.001
Laboratory characteristics
HbA1c high for agea, n (%) 169 (71.6) 115 (73.7) 32 (68.1) 22 (66.7) 0.599
Cholesterolb, n (%)
>75th percentile 86 (34.4) 51 (32.7) 26 (55.3) 9 (27.3) 0.009
LDLb, n (%)
>75th percentile 53 (22.5) 33 (21.2) 16 (34.0) 4 (12.1) 0.055
HDLb, n (%)
>75th percentile 191 (80.9) 122 (78.2) 44 (93.6) 25 (75.8) 0.046
Triglyceridesb, n (%)
>75th percentile 133 (56.4) 85 (54.5) 33 (70.2) 15 (45.5) 0.064
Urine Albuminc n (%) 0.963
Normal (<30 mg/L) 213 (90.3) 141 (90.4) 42 (89.4) 30 (90.9)
Microalbuminuria (30–299 mg/L) 22 (9.3) 14 ( 9.0) 5 (10.6) 3 (9.1)
Macroalbuminuria (≥300 mg/L) 1 (0.4) 1 (0.6) 0 (0) 0 (0)
aHbA1c is high if ≥ 8.5 % (69 mmol/mol) for < 6 years of age; ≥ 8.0 % (64 mmol/mol) for 6 – 12 years of age; ≥ 7.5 % (58 mmol/mol) for 13 – 19 years of age [2]
bPercentile categories are based from Gender and Age specific norms [19]
cUrine albumin was reported in mg/L; normal was < 30 mg/L, microalbuminuria was defined as ≥ 30 and < 300 mg/L, and macroalbuminuria was defined
as ≥ 300 mg/L [20]
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their glasses, acuity worse than 20/20 was associated
with a younger age (p = 0.042), a shorter duration of dia-
betes (p = 0.030), and type 2 diabetes (p = 0.015); 32.3 %
of participants with type 1 diabetes and 5.3 % with type
2 diabetes had 20/20 acuity in both eyes. Visual acuity
did not differ with regard to gender, race/ethnicity, re-
cency of last dilated eye exam, age at diabetes diagnosis,
or presence of DR.Discussion
Our results suggest that non-mydriatic fundus imaging
among youth with diabetes conducted at a routine endo-
crinology appointment is a feasible way to screen for
DR. Almost all parents/guardians who were approached
agreed to have their son or daughter screened, and over
97 % of participants had images that were gradable, a
rate that is comparable to other pediatric DR screening
studies using a non-mydriatic camera [13, 14]. These
Table 3 Descriptive characteristics of participants with diabetic
eye disease
Finding Total (N = 232)a (%)
Total diabetic eye disease
(including DR and maculopathy)
9 (3.9)
Background DR 7 (3.0)
Pre-proliferative DR 0 (0)
Proliferative DR 2 (0.9)
Maculopathy 1 (0.4)
Other lesions 10 (4.3)
aFour subjects were unclassifiable/ungradable for both eyes
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adult rates [21, 22], which may stem from the larger
pupil size typical of youth. Increasing age is the strongest
predictor of ungradable image rates for non-mydriatic
imaging [23]. Good imaging quality was just as likely
in younger versus older youth. The average time for
screening was brief, considerably less time than required
for a dilated eye examination. The brevity of the screen-
ing process and the reduced burden of not dilating the
pupil may facilitate increasing the number of youth
screened for DR.
A small percentage of youth screened positive for DR
(~4 %), not surprising since pediatric populations typic-
ally have a briefer duration of diabetes compared to
adults, which decreases the risk for DR [3–5]. Given that
33 % of participants in this study had not received a di-
lated eye examination in the past year or never had one,
the endocrinologist office screening represented a con-
venient opportunity to assess retinal health. The vast
majority of DR detected was background DR (7 of 9Table 4 Visual acuity among study participants
Visual acuity Total sample
(N = 231)a (%)
Omitting those who had glasses
but did not bring them to
appointment (N = 177)a (%)
Better eye acuity score
20/20 96 (41.6) 88 (49.7)
20/30 90 (39.0) 73 (41.2)
20/40 29 (12.6) 10 (5.7)
20/50 13 (5.6) 5 (2.8)
20/70 3 (1.3) 1 (0.6)
Worse eye acuity score
20/20 56 (24.2) 52 (29.4)
20/30 92 (39.8) 81 (45.8)
20/40 38 (16.5) 26 (14.7)
20/50 26 (11.3) 10 (5.7)
20/70 11 (4.8) 5 (2.8)
20/100 8 (3.5) 3 (1.7)
aFive participants were unable to perform visual acuity testcases), which suggests high potential for intervention in
DR’s earliest phases when treatment can prevent vision
loss [2].
Only 66 % of participants received a dilated eye exam
within the previous 12 months, which agrees with the
rate reported in the SEARCH for Diabetes in Youth
study [8, 9]. Even lower rates have been reported in
studies based in Philadelphia (64 %) and Ohio (53.5 %)
[24, 25]. Low rates of annual eye care utilization is con-
cerning since early DR detection and treatment reduce
the risk of irreversible vision loss [2]. Our results indi-
cate that youth with a longer duration of diabetes were
more likely to receive an eye exam within the past year,
agreeing with a recent study [14]. Although this trend is
desirable, it is still apparent that many youth with dia-
betes underutilize eye care services.
All but one parent/guardian in our study stated they
were capable of taking their child to an eye care provider
to receive a comprehensive eye care if necessary, and did
not cite barriers to care. This suggests that efforts to
improve dilated eye examination rates should focus on
educating parents/guardians about the importance of
routine eye care for youth with diabetes. Another poten-
tial mechanism underlying low dilated examination rates
among youth with diabetes may be that pediatricians
and/or endocrinologists are not effectively communi-
cating the importance of annual dilated eye care during
routine patient check-ups. Research has shown that
adults with diabetes are more compliant to vision guide-
lines when screening is routinely recommended by their
physician [26]. However, research on teenagers found
that only 35 % of teenagers with diabetes were referred
by their endocrinologist to eye care providers for annual
examinations [27]. Thus, it appears that pediatricians,
other primary care physicians, and endocrinologists
could be more vigilant in recommending annual dilated
eye examinations for their patients with diabetes.
One important aspect of any screening program is its
potential to reduce health care costs, including the
financial burden of untreated disease [28]. There is
growing evidence that non-mydriatic cameras are a cost-
effective screening tool for DR in adults with diabetes
[29]; however, there has been little research on the cost-
effectiveness of DR screening tools for youth with
diabetes. Huo et al. [30] found that implementing ADA
recommendations for annual dilated exams were not
cost effective for youth with type 1 diabetes who had ex-
cellent glycemic control, given the low rates of retinop-
athy actually present in these patients. Non-mydriatic
cameras in the endocrinology office may be a cost-
effective alternative tool for pediatric DR detection.
Most studies show a direct correlation between dur-
ation of disease and development of DR, with retino-
pathy occurring after at least 3 years since diagnosis and
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In this study, we report a mean duration of 7.8 years for
those with retinopathy compared to 5.4 years without
retinopathy (p = 0.0461). Interestingly, we identified two
cases of background retinopathy present after only
2 years since diagnosis – one case each in both a type 1
and type 2 youth with diabetes. Other studies have also
reported early retinopathy in youth with less than three
years duration [32, 33]. This is notable, considering
current ADA guidelines for type 1 diabetes recommend
screening to begin for those ≥ 10 years old having dia-
betes for 3–5 years [2]. With regard to clinical charac-
teristics, our study did not identify any significant risk
factors associated with retinopathy other than duration
of diabetes. Further studies are needed to better identify
clinical variables and their associations with DR in order
to provide more effective and targeted screening in
youth with diabetes [34].
There has been little research on vision impairment
among youth with diabetes. In our study, almost half
(49.8 %) of the sample used corrective lenses. However,
only 47 % of those with corrective lenses wore them to
their regular endocrinologist appointment at the time of
screening, suggesting that some youth with diabetes are
not wearing corrective lenses routinely even though they
have been prescribed. Further exploration may provide
insights into reasons for spectacle noncompliance in
youth with diabetes. Walk-in visual acuity for many
youth in our sample was markedly low. Even after ex-
cluding those who did not bring their corrective lenses
to the screening, 9.1 % of participants met the criteria
for visual impairment and only 29.4 % had 20/20 vision
in both eyes. As most parents/guardians of youth with
diabetes understand the importance of routine visits to
the endocrinologist and/or pediatrician, there appears to
be room for improved education on the importance of
vision care.
Strengths and limitations of this study should be
noted. To our knowledge, this is the only study that has
examined the feasibility of DR screening in youth using
a non-mydriatic camera during routine pediatric endo-
crinology clinic visits. The pediatric endocrinology clinic
serving as the study setting is in Alabama, which has the
highest rate of diabetes in the US [16]. Although the
study was unable to enroll all youth scheduled for an ap-
pointment during the study period, nearly all parents/
guardians who were invited consented to participate. A
limitation was the self-reported diabetes history and vi-
sion care utilization obtained from our survey, rather
than extracting this information from medical records.
The extent to which participants who screened positive
for DR or other ocular findings pursued follow-up exam-
inations with an ophthalmologist or optometrist was not
part of the study’s scope, but this issue will be addressedin future work. Future work should also compare the
non-mydriatic photography method used in this study to
the clinical gold-standard dilated eye examination.
Conclusion
We have shown that a non-mydriatic fundus camera is a
feasible and efficacious method to screen for diabetic
retinopathy in youth with diabetes in a region of the US
that has the highest rate of diabetes in the nation. With
approximately 1/3 of youth with diabetes not receiving
annual, dilated eye exams, screening programs imple-
mented during a routine endocrinologist appointment
may be beneficial in the management of youth with dia-
betes and prevention of irreversible vision loss, particu-
larly in those regions of the US with high diabetes rates.
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